Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | 0.022 | 0.7 |
mRNA | myricetin | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | ZSTK474 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | SB52334 | GDSC1000 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | lomeguatrib | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.7 |